The European drugs regulator is holding firm with plans to review Covid-19 vaccines designed to tackle the original coronavirus and the Omicron variant, its head said, in contrast with US authorities who plan to approve these jabs before the release of clinical data on their efficacy.
It might mean Europe receives vaccines tailored to the highly infectious BA.4 and BA.5 Omicron sub-variants later than the US.
It is unclear whether the jabs would be better than shots tailored for BA.1, a previously circulating form of Omicron, because no data is available.
您已阅读14%（561字），剩余86%（3357字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。